Omicron sub-lineage BA.5 infection results in attenuated pathology in hACE2 transgenic mice.
Journal
Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179
Informations de publication
Date de publication:
13 09 2023
13 09 2023
Historique:
received:
10
11
2022
accepted:
20
08
2023
medline:
15
9
2023
pubmed:
14
9
2023
entrez:
13
9
2023
Statut:
epublish
Résumé
A recently emerged sub-lineage of Omicron, BA.5, together with BA.4, caused a fifth wave of coronavirus disease (COVID-19) in South Africa and subsequently emerged as a predominant strain globally due to its high transmissibility. The lethality of BA.5 infection has not been studied in an acute hACE2 transgenic (hACE2.Tg) mouse model. Here, we investigated tissue-tropism and immuno-pathology induced by BA.5 infection in hACE2.Tg mice. Our data show that intranasal infection of BA.5 in hACE2.Tg mice resulted in attenuated pulmonary infection and pathology with diminished COVID-19-induced clinical and pathological manifestations. BA.5, similar to Omicron (B.1.1.529), infection led to attenuated production of inflammatory cytokines, anti-viral response and effector T cell response as compared to the ancestral strain of SARS-CoV-2, Wuhan-Hu-1. We show that mice recovered from B.1.1.529 infection showed robust protection against BA.5 infection associated with reduced lung viral load and pathology. Together, our data provide insights as to why BA.5 infection escapes previous SARS-CoV-2 exposure induced-T cell immunity but may result in milder immuno-pathology and alleviated chances of re-infectivity in Omicron-recovered individuals.
Identifiants
pubmed: 37704701
doi: 10.1038/s42003-023-05263-6
pii: 10.1038/s42003-023-05263-6
pmc: PMC10499788
doi:
Substances chimiques
Cytokines
0
Banques de données
Dryad
['10.5061/dryad.47d7wm3kt']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
935Informations de copyright
© 2023. Springer Nature Limited.
Références
Nature. 2022 Dec;612(7940):540-545
pubmed: 36323336
N Engl J Med. 2022 Mar 31;386(13):1288-1290
pubmed: 35139269
Front Immunol. 2023 Mar 07;14:1138215
pubmed: 36960064
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
Science. 2020 May 1;368(6490):473-474
pubmed: 32303591
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
Cell. 2022 Oct 13;185(21):3992-4007.e16
pubmed: 36198317
Nat Commun. 2017 Oct 9;8(1):815
pubmed: 28993609
Rev Med Virol. 2022 Sep;32(5):e2381
pubmed: 35856385
Nat Commun. 2021 Jun 1;12(1):3182
pubmed: 34075041
Front Immunol. 2021 Mar 31;12:648710
pubmed: 33868285
Signal Transduct Target Ther. 2021 Dec 17;6(1):428
pubmed: 34921131
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Science. 2020 Nov 13;370(6518):861-865
pubmed: 33082294
N Engl J Med. 2022 Sep 8;387(10):953-954
pubmed: 36044619
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Cell. 2022 Feb 3;185(3):467-484.e15
pubmed: 35081335
Clin Kidney J. 2020 Jul 16;13(3):274-280
pubmed: 32699613
Nat Med. 2022 Sep;28(9):1785-1790
pubmed: 35760080
Science. 2021 Dec 24;374(6575):1621-1626
pubmed: 34751595
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Science. 2022 May 6;376(6593):eabn4947
pubmed: 35289632
EBioMedicine. 2021 Nov;73:103642
pubmed: 34678609
J Allergy Clin Immunol. 2009 May;123(5):1026-33
pubmed: 19361845
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
Front Immunol. 2022 Sep 27;13:945583
pubmed: 36238303
Nat Commun. 2022 Aug 9;13(1):4675
pubmed: 35945213
EBioMedicine. 2022 Apr;78:103938
pubmed: 35305396
PLoS One. 2018 Dec 31;13(12):e0210116
pubmed: 30596774
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
J Virol. 2007 Jan;81(2):813-21
pubmed: 17079315
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
Nat Commun. 2022 Aug 10;13(1):4686
pubmed: 35948557
Elife. 2022 Jan 11;11:
pubmed: 35014610
Int J Infect Dis. 2020 Nov;100:327-332
pubmed: 32920235
Nature. 2022 Mar;603(7902):687-692
pubmed: 35062015
Toxicol In Vitro. 2015 Sep;29(6):1275-82
pubmed: 25448806
Front Microbiol. 2022 May 04;13:840757
pubmed: 35602059
Immunity. 2021 Feb 9;54(2):340-354.e6
pubmed: 33567252
N Engl J Med. 2022 Jul 7;387(1):86-88
pubmed: 35731894
Cell Rep Med. 2022 Jun 21;3(6):100651
pubmed: 35654046
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Science. 2022 Feb 25;375(6583):864-868
pubmed: 35076256
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Gut. 2020 Jul;69(7):1335-1342
pubmed: 32303609
Sci Adv. 2021 Sep 10;7(37):eabg5016
pubmed: 34516769
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
PLoS Pathog. 2022 Dec 12;18(12):e1010994
pubmed: 36508467
Nat Rev Cardiol. 2020 Sep;17(9):543-558
pubmed: 32690910
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
Lancet Infect Dis. 2020 May;20(5):515-516
pubmed: 32213336
Nat Immunol. 2020 Nov;21(11):1327-1335
pubmed: 32839612